Optionally substituted (1- or 3-oxy)-4,5,7,8-tetrahydro-(optionally 4-oxo, 4-thioxo or 4-imino)-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine or (1- or 3-oxy)-4,5,7,8,9-pentahydro-(optionally 4-oxo, 4-thioxo or 4-imino)-2H-pyrimido[1,2-a]pyrrolo[3,4-e]pyrimidine compounds, processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising the same.

The present invention relates to a vaginal sustained-release drug delivery system for luteal support and a method for preparation and use thereof. The vaginal sustained-release drug delivery system for luteal support is a progesterone depot-type vaginal ring having a bilayer structure of a core layer and a film layer enclosing the core layer, wherein the core layer is composed of a solid scaffold carrier of medical EVA containing a drug uniformly dispersed therein, and the film layer is composed of a medical EVA material containing no drug. The vaginal sustained-release drug delivery system for luteal support according to the present invention can be used for assisted reproduction and for treatment of functional uterine bleeding, premenstrual syndrome and the like due to luteal phase defect with a significantly improved therapeutic effect.

Provided herein are compounds, such as compounds of Formula I, that bind to androgen receptors and/or modulate activity of androgen receptors. Also provided are methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions. ##STR00001##

The present invention relates to monolithic intravaginal rings comprising progesterone, methods of making, and uses thereof. The intravaginal rings comprise progesterone, a polysiloxane elastomer, and a pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid.

The present invention relates to a vaginal sustained-release drug delivery system for luteal support and a method for preparation and use thereof. The vaginal sustained-release drug delivery system for luteal support is a progesterone depot-type vaginal ring having a bilayer structure of a core layer and a film layer enclosing the core layer, wherein the core layer is composed of a solid scaffold carrier of medical EVA containing a drug uniformly dispersed therein, and the film layer is composed of a medical EVA material containing no drug. The vaginal sustained-release drug delivery system for luteal support according to the present invention can be used for assisted reproduction and for treatment of functional uterine bleeding, premenstrual syndrome and the like due to luteal phase defect with a significantly improved therapeutic effect.

The addition of a salt to an ALA formulation that is dissolved in the mouth unexpectedly significantly reduces the degree of burning or irritation from ALA exposure during administration. This invention is particularly useful for an oral dissolved form of administration due to the extended time of ALA exposure that is possible with such formulations. The salt-inclusive formulations of the invention can increase efficacy of the ALA administration, reduce negative side effects, or both.

The addition of a salt to an ALA formulation that is dissolved in the mouth unexpectedly significantly reduces the degree of burning or irritation from ALA exposure during administration. This invention is particularly useful for an oral dissolved form of administration due to the extended time of ALA exposure that is possible with such formulations. The salt-inclusive formulations of the invention can increase efficacy of the ALA administration, reduce negative side effects, or both.

The invention relates to a method for producing a drug delivery device, which has a body comprising a siloxane-based elastomer and at least one active agent. The method comprises applying adhesive material, which comprises non-cured siloxane based elastomer, into a contact with the body and curing the said adhesive material by subjecting it to radiation energy from a laser source. The invention relates also to a drug delivery device manufactured according to the method.

The addition of a salt to an ALA formulation that is dissolved in the mouth unexpectedly significantly reduces the degree of burning or irritation from ALA exposure during administration. This invention is particularly useful for an oral dissolved form of administration due to the extended time of ALA exposure that is possible with such formulations. The salt-inclusive formulations of the invention can increase efficacy of the ALA administration, reduce negative side effects, or both.

The addition of a salt to an ALA formulation that is dissolved in the mouth unexpectedly significantly reduces the degree of burning or irritation from ALA exposure during administration. This invention is particularly useful for an oral dissolved form of administration due to the extended time of ALA exposure that is possible with such formulations. The salt-inclusive formulations of the invention can increase efficacy of the ALA administration, reduce negative side effects, or both.